The DOI matches its Crossref record; 320 of the 320 references it cites were found in a registry or an index.
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Open accessAbstract
Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed. Given the dependence on active ER signaling in these tumors, the predominant treatment strategy has been to inhibit various aspects of this pathway including directly antagonizing ER with the use of selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs). Interestingly, the dependence on ER for breast cancer growth is often retained even after progression through several lines of antiestrogen therapy, making ER a bonafide biomarker for this cancer subtype and driving the continued research and development of novel ER-targeted therapeutics to treat this patient population. This, combined with the continuous discovery of mechanisms underlying endocrine resistance, is resulting in a continually evolving treatment landscape for ER+ breast cancer. This review discusses various ER antagonists investigated for the treatment of breast cancer, outlining their pharmacological and tissue-specific mechanisms of action as well as their specified use within the ER+ breast cancer setting. In addition, mechanisms of resistance to SERMs and SERDs, the use of ER antagonists in combination therapy strategies, and the ongoing development of novel drugs are also reviewed in the context of the changing clinical landscape of ER+ breast cancer. Lastly, the role of SERMs and SERDs in non-breast cancer indications is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–320 of 320
Joseph, J. D., Darimont, B. D., Zhou, W. J., Arrazate, A., Young, A. E., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 132
The Function of Steroid Receptor Coactivator-1 in Normal Tissues and Cancer
Walsh, C. A., Qin, L., Tien, J. C.-Y., Young, L. S., & Xu, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4125 · Cited by 131
Lewis-Wambi, J. S., Kim, H., Curpan, R. F., Grigg, R., Sarker, M. A., & Jordan, V. C. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072249 · Cited by 128
Peethambaram, P. P., Ingle, J. N., Suman, V. J., Hartmann, L. C., & Loprinzi, C. L. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006185805079 · Cited by 127
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
Wardell, S. E., Nelson, E. R., Chao, C., Alley, H. M., & McDonnell, D. P. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0287 · Cited by 126
Keeton, E. K., & Brown, M. A. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0395 · Cited by 124
New biospecific adsorbents for the purification of estradiol receptor.
Bucourt, R., Vignau, M., & TORELLI, V. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34385-5 · Cited by 121
Estrogen receptor mutations and their role in breast cancer progression
Alluri, P. G., Speers, C. W., & Chinnaiyan, A. M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0494-7 · Cited by 120
Archer, D. F., Pinkerton, J. V., Utian, W. H., Menegoci, J. C., de Villiers, T. J., Yuen, C. K., Levine, A. B., Chines, A. A., & Constantine, G. D. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a818db · Cited by 119
Karlsson, E. A., Pérez‐Tenorio, G., Amin, R., Bostner, J., Skoog, L. K., Fornander, T., Sgroi, D. C., Nordenskjöld, B. A., Hallbeck, A., & Stål, O. (2013) · Breast Cancer Research · doi:10.1186/bcr3557 · Cited by 118
Said, T. K., Conneely, O. M., Medina, D., O’Malley, B. W., & Lydon, J. P. (1997) · Endocrinology · doi:10.1210/endo.138.9.5436 · Cited by 116
Schafer, J. M., Liu, H., Bentrem, D. J., Zapf, J. W., & Jordan, V. C. (2000) · PubMed · Cited by 115
Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer
Glud, E., Kjær, S. K., Thomsen, B. L., Høgdall, C. K., Christensen, L. H., Høgdall, E. V. S., Bock, J. E., & Blaakær, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.20.2253 · Cited by 115
DeMichele, A. M., Troxel, A. B., Berlin, J. A., Weber, A. L., Bunin, G. R., Turzo, E., Schinnar, R., Burgh, D. Y., Berlin, M., Rubin, S. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0921 · Cited by 115
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions
Milani, A., Geuna, E., Mittica, G., & Valabrega, G. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.990 · Cited by 114
Corson, S. L. (2006) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2006.06.015 · Cited by 112
Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780
Hu, X. F., Veroni, M., Luise, M. D., Wakeling, A. E., Sutherland, R. L., Watts, C. K. W., & Zalcberg, J. R. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550529 · Cited by 111
Yamashita, H., Nishio, M., Kobayashi, S., Ando, Y., Sugiura, H., Zhang, Z., Hamaguchi, M., Mita, K., Fujii, Y., & Iwase, H. (2005) · Breast Cancer Research · doi:10.1186/bcr1285 · Cited by 111
Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects
Omoto, Y., & Iwase, H. (2015) · Cancer Science · doi:10.1111/cas.12613 · Cited by 111
Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C. R., Peer, C. W., Wang, Y., et al. (2001) · PubMed · Cited by 111
Ahlgren, J. D., Ellison, N. M., Gottlieb, R. J., LaLuna, F. J., Lokich, J. J., Sinclair, P. R., Ueno, W. M., Wampler, G. L., Yeung, K. Y., & Alt, D. E. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1957 · Cited by 110
Ikeda, K., Horie‐Inoue, K., & Inoue, S. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.123 · Cited by 108
Mizuma, T. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.05.044 · Cited by 106
Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
Rudas, M., Lehnert, M., Huynh, A. T., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4122 · Cited by 102
Bostner, J., Karlsson, E. A., Pandiyan, M. J., Westman, H., Skoog, L. K., Fornander, T., Nordenskjöld, B. A., & Stål, O. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2376-y · Cited by 102
Fleming, F., Hill, A., Mcdermott, E., O'Higgins, N., & Young, L. (2004) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2003-031048 · Cited by 102
Kuter, I., Gee, J. M. W., Hegg, R., Singer, C. F., Badwe, R. A., Lowe, E., Emeribe, U., Anderson, E., Sapunar, F. J., Finlay, P., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1947-7 · Cited by 101
Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
Kiyotani, K., Mushiroda, T., Nakamura, Y., & Zembutsu, H. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-084 · Cited by 100
Lipton, A., Leitzel, K., Ali, S. M., et al. (2005) · Cancer · doi:10.1002/cncr.21202 · Cited by 98
Pyrhönen, S. O., Valavaara, R., Modig, H. G., Pawlicki, M., Pieńkowski, T., Gundersen, S., Bauer, J., Westman, G., Lundgren, S., Blanco, G., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.375 · Cited by 96
Multiple progesterone receptor assays in human breast cancer.
Gross, G. E., Clark, G. M., Chamness, G. C., & McGuire, W. L. (1984) · PubMed · Cited by 95
Burstein, H. J., Cirrincione, C., Barry, W. T., Chew, H. K., Tolaney, S. M., Lake, D. E., Ma, C. X., Blackwell, K., Winer, E. P., & Hudis, C. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7941 · Cited by 95
NUTTALL, M. E., Bradbeer, J. N., Stroup, G. B., Nadeau, D. P., Hoffman, S. J., Zhao, H. Q., Rehm, S., & Gowen, M. (1998) · Endocrinology · doi:10.1210/endo.139.12.6343 · Cited by 94
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer
Span, P. N., Tjan‐Heijnen, V. C. G., Manders, P., Beex, L. V. A. M., & Sweep, F. C. G. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206818 · Cited by 93
Activity of Raloxifene in Immature and Ovariectomized Rat Uterotrophic Assays
Ashby, J., Odum, J., & Foster, J. R. (1997) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1997.1108 · Cited by 93
Antiestrogens: structure-activity relationships and use in breast cancer treatment
Traboulsi, T., Ezzy, M. E., Gleason, J. L., & Mader, S. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0024 · Cited by 90
Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line
Parisot, J. P., Hu, X. F., DeLuise, M., & Zalcberg, J. R. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690112 · Cited by 88
Altucci, L., Addeo, R., Cicatiello, L., Germanò, D., Pacilio, C., Battista, T., Cancemi, M., Petrizzi, V. B., Bresciani, F., & Weisz, A. (1997) · Endocrinology · doi:10.1210/endo.138.3.5002 · Cited by 87
Poulin, R., Merand, Y., Poirier, D., Levesque, C., Dufour, J.-M., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01805977 · Cited by 86
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer
Argenta, P. A., Thomas, S. G., Judson, P. L., Downs, L. S., Geller, M. A., Carson, L. F., Jonson, A. L., & Ghebre, R. G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.01.012 · Cited by 86
Gelsomino, L., Gu, G., Rechoum, Y., Beyer, A. R., Pejerrey, S. M., Tsimelzon, A. I., Wang, T., Huffman, K. E., Ludlow, A. T., Andò, S., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3829-5 · Cited by 86
Liu, J., Zheng, S., Akerstrom, V. L., Yuan, C., Ma, Y., Zhong, Q., Zhang, C., Zhang, Q., Guo, S., Ma, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00753 · Cited by 86
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
Pinkerton, J. V., Archer, D. F., Utian, W. H., Menegoci, J. C., Levine, A. B., Chines, A. A., & Constantine, G. D. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a816be · Cited by 85
Nicholson, R. I., Gee, J. M. W., Manning, D. L., Wakeling, A. E., Montano, M. M., & Katzenellenbogen, B. S. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31376.x · Cited by 84
Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E. P., Fredrickson, J. O., Arteaga, C. L., Baselga, J. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2197 · Cited by 83
McMeekin, D. S., Gordon, A. N., Fowler, J. M., Melemed, A. S., Buller, R. E., Burke, T. J., Bloss, J., & Sabbatini, P. J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00203-8 · Cited by 82
Oestrogen receptor β in breast cancer: good, bad or still too early to tell?
Speirs, V. (2002) · The Journal of Pathology · doi:10.1002/path.1072 · Cited by 80
Drury, S., DETRE, S. I., Leary, A. F., Salter, J., Reis-Filho, J. S., Barbashina, V., Marchiò, C., López‐Knowles, E., Ghazoui, Z. F., Habben, K., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0046 · Cited by 79
Gershanovich, M., Garin, A. M., Baltina, D., Kurvet, A., Kangas, L., Ellmén, J., & Eastern European Study Group (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005891506092 · Cited by 78
Tomita, S., Zhang, Z., Nakano, M., Ibusuki, M., Kawazoe, T., Yamamoto, Y., & Iwase, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01145.x · Cited by 78
Molecularly targeted endocrine therapies for breast cancer
Orlando, L., Schiavone, P., Fedele, P., Calvani, N., Nacci, A., Rizzo, P., Marino, A., D’amico, M., Sponziello, F., Mazzoni, E., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70023-2 · Cited by 78
A Good Drug Made Better: The Fulvestrant Dose-Response Story
Robertson, J. F. R., Lindemann, J. P. O., Garnett, S., Anderson, E., Nicholson, R. I., Kuter, I., & Gee, J. M. W. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.005 · Cited by 75
Deshmane, V., Krishnamurthy, S., Melemed, A. S., Peterson, P. M., & Buzdar, A. U. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.5992 · Cited by 75
Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 Model
Jeong, E. J., Lin, H., & Hu, M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063925 · Cited by 75
Covens, A. L., Filiaci, V. L., Gersell, D. J., Lutman, C. V., Bonebrake, A. J., & Lee, Y.-C. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.10.015 · Cited by 74
Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 74
Hurteau, J. A., Brady, M. F., Darcy, K. M., McGuire, W. P., Edmonds, P. R., Pearl, M. L., Ivanov, I., Tewari, K. S., Mannel, R. S., Zanotti, K. M., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.002 · Cited by 73
Lippman, M. E., Cummings, S. R., Disch, D. P., Mershon, J. L., Dowsett, S. A., Cauley, J. A., & Martino, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0688 · Cited by 73
The 2.0 Å crystal structure of the ERα ligand‐binding domain complexed with lasofoxifene
Vajdos, F. F., Hoth, L. R., Geoghegan, K. F., Simons, S. P., LeMotte, P. K., Danley, D. E., Ammirati, M. J., & Pandit, J. (2007) · Protein Science · doi:10.1110/ps.062729207 · Cited by 71
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
Pérez‐Tenorio, G., Karlsson, E. A., Waltersson, M. A., Olsson, B., Holmlund, B., Nordenskjöld, B. A., Fornander, T., Skoog, L. K., & Stål, O. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1058-x · Cited by 71
Goldstein, S. R., Neven, P., Cummings, S. R., Colgan, T. J., Runowicz, C. D., Krpan, D., Proulx, J., Johnson, M. R., Thompson, D., Thompson, J. R., et al. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181e84bb4 · Cited by 70
Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
Grady, D. L., Cauley, J. A., Geiger, M. J., Kornitzer, M., Mosca, L. J., Collins, P., WENGER, N. K., Song, J., Mershon, J. L., Barrett-Connor, E. L., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn153 · Cited by 70
Gray, R. G., Rea, D. W., Handley, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.513 · Cited by 69
Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors
Dodwell, D. J., Wardley, A. M., & Johnston, S. R. D. (2006) · The Breast · doi:10.1016/j.breast.2006.01.007 · Cited by 69
Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
Kok, M., Holm, C., Hauptmann, M., Michalides, R. J. A. M., Stål, O., Linn, S. C., & Landberg, G. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp412 · Cited by 68
Buzdar, A. U., Hayes, D. F., El-Khoudary, A., Yan, S., Lønning, P. E., Lichinitser, M., Gopal, R., Falkson, G., Pritchard, K. I., Lipton, A., et al. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1015229630260 · Cited by 67
Morgan, L. D., Gee, J. M. W., Pumford, S. L., Farrow, L., Finlay, P., Robertson, J. F. R., Ellis, I. O., Kawakatsu, H., Nicholson, R. I., & Hiscox, S. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.16.8954 · Cited by 66
Massarweh, S. A., Romond, E. H., Black, E. P., Dressler, E. V. M., Shelton, B. J., Kadamyan, V., Stevens, M., & Elledge, R. M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2810-9 · Cited by 65
Diethylstilbestrol: Recommended Dosages for Different Categories of Breast Cancer Patients
Carter, A. C. (1977) · JAMA · doi:10.1001/jama.1977.03270460065023 · Cited by 64
Nielsen, K. V., Ejlertsen, B., Müller, S., Möller, S., Rasmussen, B., Balslev, E., Lænkholm, A., Christiansen, P., & Mouridsen, H. T. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0984-y · Cited by 60
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios, C. H., Forbes, J., Jonat, W., Conte, P., Gradishar, W. J., Buzdar, A. U., Gelmon, K. A., Gnant, M., Bonneterre, J. M., Toi, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr593 · Cited by 59
Pharmacogenetics of Tamoxifen: Who Should UndergoCYP2D6Genetic Testing?
Higgins, M. J., Rae, J. M., Flockhart, D. A., Hayes, D. F., & Stearns, V. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0014 · Cited by 58
Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
Somlo, G. (2014) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2014.10.021 · Cited by 58
Oestrogen Receptors and Selective Oestrogen Receptor Modulators: Molecular and Cellular Pharmacology
Nilsson, S. V., & Koehler, K. F. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960103.x · Cited by 58
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Andersen, C. L., Sikora, M. J., Boisen, M. M., Ma, T., Christie, A., Tseng, G. C., Park, Y., Luthra, S., Chandran, U. R., Haluska, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1501 · Cited by 58
Fedele, P., Calvani, N., Marino, A., Orlando, L., Schiavone, P., Quaranta, A., & Cinieri, S. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.004 · Cited by 55
Dirix, L. Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1562 · Cited by 54
Kok, M., Zwart, W. T., Holm, C., Fles, R., Hauptmann, M., Veer, L. J. V., Wessels, L. F. A., Neefjes, J., Stål, O., Linn, S. C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0798-y · Cited by 53
Pohl, G., Rudas, M., Dietze, O., Lax, S., Markis, E., Pirker, R., Zielinski, C. C., Hausmaninger, H., Kubista, E., Samonigg, H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.021 · Cited by 53
Veeraraghavan, J., Ma, J., Hu, Y., & Wang, X.-S. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3876-y · Cited by 52
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Augereau, P., Patsouris, A., Bourbouloux, E., Gourmelon, C., Lacourtoisie, S. A., Rigaud, D. B., Soulié, P., Frenel, J., & Campone, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693195 · Cited by 50
Bad expression predicts outcome in patients treated with tamoxifen
Cannings, E., Kirkegaard, T., Tovey, S., Dunne, B., Cooke, T. G., & Bartlett, J. M. S. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9323-8 · Cited by 49
Beelen, K. J., Opdam, M., Severson, T., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J. F., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3598 · Cited by 48
Greenberger, L. M., Annable, T., Collins, K., Komm, B. S., Lyttle, C. R., MILLER, C. P., SATYASWAROOP, P. G., Zhang, Y., & Frost, P. (2001) · PubMed · Cited by 48
Zhou, W., Ding, Q., Chen, L., Liu, X., & Wang, S. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1556-5 · Cited by 44
Romano, A., Adriaens, M. E., Kuenen, S., Delvoux, B., Dunselman, G. A. J., Evelo, C. T., & Groothuis, P. G. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.08.008 · Cited by 44
Dardes, R. C., O'Regan, R. M., Gajdos, C., Robinson, S. P., Bentrem, D. J., Reyes, A. D. L., & Jordan, V. C. (2002) · PubMed · Cited by 41
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
Howell, A., & Robertson, J. F. R. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90739-4 · Cited by 41
Dayan, G., Lupien, M., Auger, A., Anghel, S. I., Rocha, W., Croisetière, S., Katzenellenbogen, J. A., & Mader, S. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021931 · Cited by 38
Jansson, A., Delander, L., Gunnarsson, C., Fornander, T., Skoog, L. K., Nordenskjöld, B. A., & Stål, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2599 · Cited by 36
Ponzone, R., Montemurro, F., Maggiorotto, F., Robba, C., Gregori, D., Jacomuzzi, M. E., Kubatzki, F., Marenco, D., Dominguez, A., Biglia, N., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl296 · Cited by 36
Arpino, G., Krishnan, M. N., Dinesh, C., Bardou, V. J., Clark, G. M., & Elledge, R. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg097 · Cited by 36
Toremifene versus tamoxifen for advanced breast cancer
Mao, C., Yang, Z., He, B., Liu, S., Zhou, J., Luo, R., Chen, Q., & Tang, J.-L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008926.pub2 · Cited by 33
Glück, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.08.004 · Cited by 33
Breast cancer: Aromatase inhibitors take on tamoxifen
Dowsett, M., & Howell, A. (2002) · Nature Medicine · doi:10.1038/nm1202-1341 · Cited by 32
Role of SUMOylation in Full Antiestrogenicity
Hilmi, K., Hussein, N., Mendoza‐Sanchez, R., Ezzy, M. E., Ismail, H., Durette, C., Bail, M., Rozendaal, M. J., Bouvier, M., Thibault, P., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00290-12 · Cited by 32
Beelen, K. J., Hoefnagel, L. D. C., Opdam, M., Wesseling, J., Sanders, J., Vincent, A. D., van Diest, P. J., & Linn, S. C. (2014) · International Journal of Cancer · doi:10.1002/ijc.28769 · Cited by 31
Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Newby, J. A., & Dowsett, M. (1995) · Endocrine Related Cancer · doi:10.1677/erc.0.0020105 · Cited by 31
The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation
Zhang, H., McElrath, T., Tong, W., & Pollard, J. W. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05987 · Cited by 31
Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer
Huang, D., Yang, F., Wang, Y., & Guan, X. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.008 · Cited by 31
Stendahl, M., Nilsson, S., Wigerup, C., Jirström, K., Jönsson, P., Stål, O., & Landberg, G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25297 · Cited by 30
Roberts, C. G., Millar, E. K. A., O'Toole, S. A., McNeil, C. M., Lehrbach, G. M., Pinese, M., Tobelmann, P. E., McCloy, R. A., Musgrove, E. A., Sutherland, R. L., et al. (2011) · Oncogene · doi:10.1038/onc.2011.36 · Cited by 29
Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women
Gardner, M., Taylor, A. E., Wei, G. C. G., Calcagni, A., Duncan, B. A., & Milton, A. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283280 · Cited by 29
Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer
Parl, F. F. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500201 · Cited by 28
Gockerman, J. P., Spremulli, E. N., Raney, M. R., & Logan, T. F. (1986) · PubMed · Cited by 28
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate
Holst, F. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i2.160 · Cited by 27
Mahon, J., Feagan, B., & Laupacis, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90738-6 · Cited by 26
Lasofoxifene in Postmenopausal Women With Osteoporosis
Cummings, S. R., Ensrud, K. E., Delmas, P. D., LaCroix, A. Z., Vukičević, S., Reid, D. M., Goldstein, S. R., Sriram, U., Lee, A., Thompson, J. R., et al. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181e5f28b · Cited by 25
Moyle-Heyrman, G., Schipma, M. J., Dean, M., Davis, D. A., & Burdette, J. E. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0213-3 · Cited by 22
Gumbrell, L. A., Evans, T. R. J., Coleman, R. E., Smith, I. E., Twelves, C. J., Soukop, M., Rea, D., Earl, H. M., Howell, A., Jones, A. L., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0733-6 · Cited by 21
Cotreau, M. M., Stonis, L., Dykstra, K. H., Gandhi, T., Gutierrez, M., Jing, X., Park, Y., Burghart, P. H., & Schwertschlag, U. S. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011193 · Cited by 20
Yoneya (2009) · Oncology Reports · doi:10.3892/or_00000280 · Cited by 17
Ye, Q.-L., & Zhai, Z. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2914-7 · Cited by 14
Prognostic variables in node-negative and node-positive breast cancer — editorial
Gasparini, G. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5195-9_30 · Cited by 12
Tabarestani, S., Ghaderian, S. M. H., Rezvani, H., & Mirfakhraie, R. (2014) · Medical Oncology · doi:10.1007/s12032-014-0896-5 · Cited by 12
Zhang, Z., Yamashita, H., Toyama, T., Yamamoto, Y., Kawasoe, T., Ibusuki, M., Tomita, S., Sugiura, H., Kobayashi, S., Fujii, Y., et al. (2009) · PubMed · Cited by 11
Källström, A.-C., Salme, R., Rydén, L., Nordenskjöld, B. A., Jönsson, P., & Stål, O. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.016 · Cited by 11
Boisen, M. M., Andersen, C. L., Sreekumar, S., Stern, A. M., & Oesterreich, S. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.04.035 · Cited by 10
Toremifene versus tamoxifen for advanced breast cancer
Mao, C., He, B., Liu, S., Zhou, J., Qiu, L., Luo, R., & Chen, Q. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008926 · Cited by 9
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
The lingering mysteries of metastatic recurrence in breast cancer
Riggio, A. I., Varley, K. E., & Welm, A. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01161-4 · Cited by 616
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
Metadata
- Authors
- Patel, H. K., & Bihani, T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 186
- Pages
- 1-24
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2777085303
- Cited by
- 499
- References
- 320
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.